tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AKLI

Akili’s Acquisition by Virtual Therapeutics and Nasdaq Delisting
Company AnnouncementsAkili’s Acquisition by Virtual Therapeutics and Nasdaq Delisting
5M ago
8K
AKLI
Akili announces FDA authorization of EndeavorOTC
PremiumThe Fly
Akili announces FDA authorization of EndeavorOTC
5M ago
AKLI
Akili Announces Merger Agreement and Recommends Shareholder Approval
PremiumCompany Announcements
Akili Announces Merger Agreement and Recommends Shareholder Approval
6M ago
8K
AKLI
Akili to go private through merger agreement with Virtual Therapeutics
PremiumThe Fly
Akili to go private through merger agreement with Virtual Therapeutics
6M ago
AKLI
Akili to go private through merger agreement with Virtual Therapeutics
PremiumThe Fly
Akili to go private through merger agreement with Virtual Therapeutics
6M ago
AKLI
Akili reports Q1 net loss ($9.3M) vs. ($13.6M) last year
PremiumThe FlyAkili reports Q1 net loss ($9.3M) vs. ($13.6M) last year
7M ago
AKLI
Is AKLI a Buy, Before Earnings?
Premium
Pre-Earnings
Is AKLI a Buy, Before Earnings?
7M ago
AKLI
Akili partner in Japan submits SDT-001 for marketing approval
Premium
The Fly
Akili partner in Japan submits SDT-001 for marketing approval
9M ago
AKLI
Akili Enhances Board and Announces Financial Results
PremiumCompany Announcements
Akili Enhances Board and Announces Financial Results
9M ago
8K
AKLI
Akili sees cash, equivalents sufficient to fund operations into 2H25
PremiumThe Fly
Akili sees cash, equivalents sufficient to fund operations into 2H25
1y ago
AKLI
Akili reports Q3 revenue $702,000, consensus $22,000
PremiumThe Fly
Akili reports Q3 revenue $702,000, consensus $22,000
1y ago
AKLI
Akili participates in a conference call with LifeSci Capital
PremiumThe Fly
Akili participates in a conference call with LifeSci Capital
1y ago
AKLI
Akili CEO Eddie Martucci transitions to board chair, Matt Franklin to succeed
PremiumThe FlyAkili CEO Eddie Martucci transitions to board chair, Matt Franklin to succeed
1y ago
AKLI
Akili participates in a conference call with LifeSci Capital
Premium
The Fly
Akili participates in a conference call with LifeSci Capital
1y ago
AKLI
Akili participates in a conference call with LifeSci Capital
Premium
The Fly
Akili participates in a conference call with LifeSci Capital
1y ago
AKLI
Akili sees FY23 total operating expenses $55M-$60M
PremiumThe Fly
Akili sees FY23 total operating expenses $55M-$60M
1y ago
AKLI
Akili plans to transition to a non-prescription model, reduce headcount by 40%
PremiumThe Fly
Akili plans to transition to a non-prescription model, reduce headcount by 40%
1y ago
AKLI
Akili reports Q2 revenue $114,000, consensus $240,000
PremiumThe Fly
Akili reports Q2 revenue $114,000, consensus $240,000
1y ago
AKLI
Akili reports Q4 non-GAAP net loss ($19.54M) vs ($18.246M) last year
PremiumThe Fly
Akili reports Q4 non-GAAP net loss ($19.54M) vs ($18.246M) last year
2y ago
AKLI
Akili: EndeavorRx trial to treat ADHD in adolescents shows robust improvements
PremiumThe FlyAkili: EndeavorRx trial to treat ADHD in adolescents shows robust improvements
2y ago
AKLI
Akili initiated with an Equal Weight at Morgan Stanley
Premium
The Fly
Akili initiated with an Equal Weight at Morgan Stanley
2y ago
AKLI
Akili Interactive appoints Scott Kollins as chief medical officer
Premium
The Fly
Akili Interactive appoints Scott Kollins as chief medical officer
2y ago
AKLI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >